Tuberculosis, the world’s leading infectious killer, may have finally met its match. Two new drug therapies may be able to cure all forms of tuberculosis – even the ones most difficult to treat. “We will have something to offer every single patient,” says Mel Spigelman, president ...

SEATTLE — Data from a study of HIV–infected infants who received early ART suggest the reservoir for HIV lies in cells that were infected before ART initiation. “This is important because we have to understand what the reservoir is to be able to target it and ...

Bictegravir, an investigational integrase inhibitor from Gilead Sciences, was highly potent, well tolerated and worked as well as dolutegravir (Tivcay) in a phase 2 clinical trial, according to study results presented on Tuesday at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle ...

New Rochelle, NY, February 9, 2017—A comprehensive collection of articles describing the broad scope and current status of this global effort is published in a special issue of AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The third annual ...

Following individuals through the cascade of care, from HIV diagnosis to treatment and undetectable viral load, rather than taking snapshots of performance, has led researchers on a major South African study to pinpoint linkage to care after testing HIV positive as the biggest weakness of ...

A new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide. The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) will evaluate a new vaccine that triggers the ...

Researchers from the Dutch pre-exposure prophylaxis (PrEP) demonstration study, AmPrEP, have found an unexpectedly high rate of hepatitis C virus (HCV) infection in participants tested for it at baseline. The HCV prevalence seen was more typical of that seen in HIV-positive gay men rather than the ...

Researchers recently published their findings on a combination therapy for use in patients with hepatitis C (HCV) genotype 4 in PLoS One. According to the Belgian researchers, sofosbuvir in combination with simeprevir with or without ribarivirn was found to be safe and effective. According to the ...

Summary Background Sex workers are disproportionately affected by HIV compared with the general population. Most studies of HIV risk among sex workers have focused on individual-level risk factors, with few studies assessing potential structural determinants of HIV risk. In this Article, we examine whether criminal laws around ...

PARIS, February 02, 2017 – ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, announced today that the previously disclosed results of its two Phase I trials with ABX464 in healthy volunteers have now been ...

U.S. FDA grants priority review to AbbVie for its investigational regimen of glecaprevir/pibrentasvir (G/P) for the treatment of chronic hepatitis C in all major genotypes (GT1-6) – If approved, G/P will provide an eight week, once-daily, ribavirin-free cure* for HCV patients without cirrhosis across all major ...

In first-ever study, Case School of Medicine researchers to pair monoclonal antibody with body’s own killer-cell stimulator Newswise — A Case Western Reserve University School of Medicine researcher has received a $2.5 million grant from Gilead Sciences, a California-based biopharmaceutical company, to see if two so-far ...

A research team at UNMC has used a process they call LASER ART (long-acting slow effective release antiretroviral therapy) to discover an unexpected pathway to open cell storage areas for antiviral drugs. The discovery could revolutionize current treatments for HIV/AIDS by extending the actions of ...

Fast-track the end of AIDS in the EU – practical evidence-based interventions In a two-day conference organised in collaboration between the Maltese Presidency of the Council of the European Union and ECDC, HIV experts from across the European Union discuss how to reverse this trend and ...

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that the clinical development program for RG-101 remains on clinical hold. In ...

No new HIV infections have been seen among nearly 1000 people who started Truvada for pre-exposure prophylaxis (PrEP) at Kaiser Permanente Northern California, according to a recent report in the Journal of Acquired Immune Deficiency Syndromes. The most recent analysis shows, however, that incidence of ...

The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales. Epclusa – a once-daily, fixed-dose combination of the nucleotide ...

Study finds good nutrition improves medication adherence and mental health HIV-positive people who received healthy food and snacks for six months were more likely to adhere to their medication regimens, and they, as well as people with type 2 diabetes, were less depressed and less likely ...